Novartis Korea Launches Domestic Phase 3 Clinical Trial of Aliskiren

Published: 2004-12-10 06:56:00
Updated: 2004-12-10 06:56:00
Novartis Korea announced on December 9th that the international Phase 3 clinical trial of its anti-hypertension drug Aliskiren (SPP100), a renin inhibitor, will also take place in Korea along with four other countries.

According to Novartis Korea, Aliskiren (SPP100) is the first orally active ...

Fees

- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.



Most Read News


TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.